{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:29:07Z","timestamp":1790908147996,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.3816\/clm.2008.s.015","type":"journal-article","created":{"date-parts":[[2008,12,16]],"date-time":"2008-12-16T02:03:23Z","timestamp":1229393003000},"page":"S187-S192","source":"Crossref","is-referenced-by-count":29,"special_numbering":"S5","title":["Novel Therapies for Cutaneous T-Cell Lymphomas"],"prefix":"10.3816","volume":"8","author":[{"given":"Steven M.","family":"Horwitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2008.s.015_bib1","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.s.015_bib2","doi-asserted-by":"crossref","first-page":"436","DOI":"10.6004\/jnccn.2008.0033","article-title":"Review of the treatment of mycosis fungoides and s\u00e9zary syndrome: a stage-based approach","volume":"6","author":"Horwitz","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"10.3816\/CLM.2008.s.015_bib3","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.015_bib4","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.015_bib5","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.3816\/CLM.2008.s.015_bib6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1396-0296.2003.01639.x","article-title":"Treatment of patch-stage mycosis fungoides with topical corticosteroids","volume":"16","author":"Zackheim","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.3816\/CLM.2008.s.015_bib7","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archderm.134.8.949","article-title":"Topical corticosteroids for mycosis fungoides. Experience in 79 patients","volume":"134","author":"Zackheim","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.3816\/CLM.2008.s.015_bib8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archderm.139.2.165","article-title":"Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.3816\/CLM.2008.s.015_bib9","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0190-9622(03)01475-0","article-title":"Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial","volume":"49","author":"Heald","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CLM.2008.s.015_bib10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/archderm.141.3.305","article-title":"Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy","volume":"141","author":"Querfeld","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.3816\/CLM.2008.s.015_bib11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1067\/mjd.2002.120911","article-title":"Narrowband UVB phototherapy for early-stage mycosis fungoides","volume":"47","author":"Gathers","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CLM.2008.s.015_bib12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1396-0296.2003.01647.x","article-title":"Mycosis fungoides: radiation therapy","volume":"16","author":"Hoppe","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.3816\/CLM.2008.s.015_bib13","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.015_bib14","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.3816\/CLM.2008.s.015_bib15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2008.s.015_bib16","first-page":"447s","article-title":"Efficacy and safety of denileukin diftitox (Dd) in a phase III, double-blind, placebo-controlled study of CD25+ patients with cutaneous T-cell lymphoma (CTCL)","volume":"25","author":"Negro-Vilar","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.015_bib17","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3816\/CLM.2001.n.005","article-title":"Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication","volume":"1","author":"Foss","year":"2001","journal-title":"Clin Lymphoma"},{"key":"10.3816\/CLM.2008.s.015_bib18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.canlet.2008.03.037","article-title":"Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy","volume":"269","author":"Carew","year":"2008","journal-title":"Cancer Lett"},{"key":"10.3816\/CLM.2008.s.015_bib19","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.015_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) [published erratum appears in: Blood 2007; 109:5086]","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"issue":"suppl 4","key":"10.3816\/CLM.2008.s.015_bib21","first-page":"iv116","article-title":"International trial confirms romidepsin efficacy in refractory CTCL patients","volume":"19","author":"Prentice","year":"2008","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2008.s.015_bib22","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1158\/1078-0432.CCR-05-2095","article-title":"Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma","volume":"12","author":"Piekarz","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2008.s.015_bib23","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/1042819031000077124","article-title":"Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression","volume":"44","author":"Wang","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2008.s.015_bib24","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2141.2007.06658.x","article-title":"Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma","volume":"139","author":"O'Connor","year":"2007","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2008.s.015_bib25","first-page":"122a","article-title":"Pralatrexate (PDX) produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral T-cell lymphomas: results of the MSKCC phase I\/II experience","volume":"108","author":"O'Connor","year":"2006","journal-title":"Blood"},{"issue":"suppl 4","key":"10.3816\/CLM.2008.s.015_bib26","first-page":"iv162","article-title":"Low-dose pralatrexate (PDX) is active in cutaneous T-cell lymphoma: preliminary results of a multi-center dose finding trial","volume":"19","author":"Horwitz","year":"2008","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2008.s.015_bib27","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM198702053160603","article-title":"Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results","volume":"316","author":"Edelson","year":"1987","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2008.s.015_bib28","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1396-0296.2003.01646.x","article-title":"The treatment of cutaneous T-cell lymphoma with photopheresis","volume":"16","author":"Zic","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.3816\/CLM.2008.s.015_bib29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1749-6632.2001.tb03721.x","article-title":"The role for interleukin-12 therapy of cutaneous T cell lymphoma","volume":"941","author":"Rook","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.3816\/CLM.2008.s.015_bib30","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1046\/j.1523-1747.2002.01646.x","article-title":"Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma","volume":"118","author":"Zaki","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.3816\/CLM.2008.s.015_bib31","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jaad.2006.08.067","article-title":"Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and S\u00e9zary syndrome","volume":"56","author":"Querfeld","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CLM.2008.s.015_bib32","doi-asserted-by":"crossref","first-page":"6168","DOI":"10.1158\/1078-0432.CCR-07-0815","article-title":"Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma","volume":"13","author":"Leonard","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2008.s.015_bib33","first-page":"936a","article-title":"Preliminary results of a phase II study of CC-5013 (lenalidomide, Revlimid\u00ae) in patients with cutaneous T-cell lymphoma","volume":"106","author":"Querfeld","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.015_bib34","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1182\/blood-2002-08-2455","article-title":"Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells","volume":"102","author":"Maier","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.015_bib35","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1002\/eji.200324244","article-title":"Anti-tumor immune responses and tumor regression induced with mimotopes of a tumor-associated T cell epitope","volume":"33","author":"Tumenjargal","year":"2003","journal-title":"Eur J Immunol"},{"key":"10.3816\/CLM.2008.s.015_bib36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","article-title":"Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.3816\/CLM.2008.s.015_bib37","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21449","article-title":"Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients","volume":"104","author":"Marchi","year":"2005","journal-title":"Cancer"},{"key":"10.3816\/CLM.2008.s.015_bib38","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cncr.11593","article-title":"Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma","volume":"98","author":"Wollina","year":"2003","journal-title":"Cancer"},{"key":"10.3816\/CLM.2008.s.015_bib39","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.015_bib40","doi-asserted-by":"crossref","first-page":"698a","DOI":"10.1182\/blood.V108.11.2467.2467","article-title":"Oral forodesine (Bcx-1777) is clinically active in refractory cutaneous T-cell lymphoma: results of a phase I\/II study","volume":"108","author":"Duvic","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.015_bib41","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/cncr.22596","article-title":"Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma","volume":"109","author":"Straus","year":"2007","journal-title":"Cancer"},{"key":"10.3816\/CLM.2008.s.015_bib42","first-page":"29","article-title":"Optimal combination with PUVA: rationale and clinical trial update","volume":"21","author":"Stadler","year":"2007","journal-title":"Oncology (Williston Park)"},{"issue":"15 suppl","key":"10.3816\/CLM.2008.s.015_bib43","first-page":"481s","article-title":"Phase I trial of oral vorinostat in combination with bexarotene in patients with advanced cutaneous T-cell lymphoma","volume":"26","author":"Hymes","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.015_bib44","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2004-11-4570","article-title":"A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"106","author":"Foss","year":"2005","journal-title":"Blood"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011702773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011702773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T20:03:10Z","timestamp":1589400190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011702773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":44,"alternative-id":["S1557919011702773"],"URL":"https:\/\/doi.org\/10.3816\/clm.2008.s.015","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}